Sinopharm Group Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Sinopharm Group (HKG:1099) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥596.6b (up 8.0% from FY 2022).
• Net income: CN¥9.05b (up 6.2% from FY 2022).
• Profit margin: 1.5% (in line with FY 2022).
• EPS: CN¥2.91 (up from CN¥2.73 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sinopharm Group EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 1.9%.

The primary driver behind last 12 months revenue was the Pharmaceutical Distribution segment contributing a total revenue of CN¥441.1b (74% of total revenue). Notably, cost of sales worth CN¥548.1b amounted to 92% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥17.5b (44% of total expenses). Explore how 1099's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Hong Kong.

Performance of the Hong Kong Healthcare industry.

The company's shares are down 2.9% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Sinopharm Group's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.